Cognitive Dysfunction in Parkinson Disease

Authors

  • N.Z. Agaeva Medical Center of "New Medical Technologies" LTD, Baku, Azerbaijan
  • S.R. Hasanli Baku Slavic University, Pedagogy and Psychology department, Baku, Azerbaijan
  • R.L. Gasanov Azerbaijan State Advanced Training Institute for Doctors named after A.Aliyeva, Department of Neurology and Clinical Neurophysiology, Baku, Azerbaijan

DOI:

https://doi.org/10.61788/njn.v1i22.08

Keywords:

Parkinson disease, non-motor signs, mild cognitive impairment

Abstract

Parkinson’s disease is the second most common progressive neurodegenerative disorder mainly in middle-elderly population. Particular attention is paid to the evaluation and correction of cognitive disorders among non-motor manifestations of the disease. The purpose of this scientific study was to study the features of clinical deficiency in Parkinson's disease. The study included 36 patients who underwent clinical and neurological assessment, as well as neuropsychological testing according to the MOCA and Hoehn Yahr scales. Thus, according to the results of the study, a direct correlation was found between the severity of the disease and the degree of cognitive impairment.

References

Kalia L.V., Lang A.E. Parkinson’s disease // 2e Lancet, 2015, vol. 386, no. 9996, pp. 896-912.

Hely M.A., Reid W.G.J., Adena M.A., Halliday G.M., Morris J.G.L. +e Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years // Movement Disorders, 2008, vol. 23, no. 6, pp. 837-844.

Pfeiffer H.C.V., Løkkegaard A., Zoetmulder M., Friberg L., Werdelin L. Cognitive impairment in early-stage nondemented Parkinson’s disease patients // Acta Neurologica Scandinavica, 2014, vol. 129, no. 5, pp. 307-318.

Anna B. Cortical 6-[18F]fluoro-l-dopa uptake and frontal cognitive functions in early Parkinson’s disease // Neurobiology of Aging, 2005, vol. 26, pp. 891-898.

Bohnen N.I., Albin R.L. +e cholinergic system and Parkinson disease // Behavioural Brain Research, 2011, vol. 221, no. 2, pp. 564-573.

Perry E.K., Curtis M., Dick D.J. et al. Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease // Journal of Neurology, Neurosurgery & Psychiatry, 1985, vol. 48, no. 5, pp. 413-421.

Bohnen N.I., Kaufer D.I., Ivanco L.S. et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in alzheimer disease // Archives of Neurology, 2003, vol. 60, no. 12, pp. 1745-1748.

Emre M., Aarsland D., Albanese A. et al. Rivastigmine for dementia associated with Parkinson’s disease // New England Journal of Medicine, 2004, vol. 351, no. 24, pp. 2509-2518.

Leung I.H.K., Walton C.C., Hallock H., Lewis S.J.G., Valenzuela M., Lampit A. Cognitive training in Parkinson disease // Neurology, 2015, vol. 85, no. 21, pp. 1843-1851.

Murray D.K. +e effects of exercise on cognition in Parkinson’s disease: a systematic review // Transl Neurodegener, 2014, vol. 3, no. 1, p. 5.

Zimmermann R., Gschwandtner U., Benz N. et al. Cognitive training in Parkinson disease: cognition-specific vs. nonspecific computer training // Neurology, 2014, vol. 82, no. 14, pp. 1219-122.

Алиева Ф.Н. Заболеваемость и распространенность болезни Паркинсона в Баку // Журнал неврологии и психиатрии им. С.С. Корсакова, 2021; 121 (11): 7780. https://doi.org/10.17116/jnevro202112111177

Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment // J Am Geriatr Soc. 2005 Apr;53(4):695-9.

Downloads

Published

30.06.2022

How to Cite

Agaeva, N., Hasanli, S., & Gasanov, R. (2022). Cognitive Dysfunction in Parkinson Disease. National Journal of Neurology, 54–56. https://doi.org/10.61788/njn.v1i22.08

Issue

2022: No.1 (21)

Section

Original Articles

License

Copyright (c) 2026 National Association of Neurologists

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.